Vertex shares halted following report of FDA approval

Shares of Vertex Pharmaceuticals Inc. rose Thursday before being halted following a report that the biotech received Food and Drug Administration approval for a cystic fibrosis treatment. Shares of Vertex rose 3.7% to $130.90 before being halted pending news from the company. The Boston Globe reported that Vertex recieved marketing approval for its cystic fibrosis treatment Orkambi.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.